Introduction {#Sec1}
============

Creutzfeldt-Jakob disease (CJD) is a rapidly progressive neurodegenerative disease. Presently, the definite diagnosis of CJD requires neuropathological confirmation. Cerebrospinal fluid (CSF) analysis plays an important role in the diagnosis of CJD. After the WHO consultation in 1998, a positive 14-3-3 result is considered as a criterion of probable sporadic CJD (sCJD) \[[@CR12]\]. Different studies have shown that in the appropriate clinical circumstances a positive 14-3-3 is highly sensitive and specific for the diagnosis of sCJD \[[@CR14]\]. However, the question remains open as to whether 14-3-3 is more sensitive in the initial or late stages of disease. Increased levels of other brain-derived proteins, such as microtubule-associated tau protein \[[@CR8]\], S100b \[[@CR4]\] or neurone specific enolase (NSE) \[[@CR13]\] have also been reported to be elevated in CSF in CJD. The published data about how the levels of these proteins are modified during the course of disease are contradictory \[[@CR1]--[@CR3], [@CR5]--[@CR7], [@CR10], [@CR11]\]. In addition, the time point during the disease, when biochemical markers are expected to have the highest sensitivity, is not well-defined. These topics have not been studied systematically, especially because data from sequential CSF analyses are rarely available.

In the framework of an European Community supported multinational study on CJD markers, we performed an analysis of the results obtained in different stages of the disease and in repeated lumbar punctures (LP) to assess the influence of time of sampling on the value of CSF tests in the diagnosis of sCJD.

Methods {#Sec2}
=======

Study overview {#Sec3}
--------------

This study was conducted in the framework of a European Community supported multinational study (Early clinical diagnosis of human spongiform encephalopathies by analysis of biological fluids (CJDmarkers), (QLG3-CT-2002-81606 Coordinator: I. Zerr). All participant countries belong to the EUROCJD Surveillance network with comparable surveillance methods. CSF samples were sent to the individual laboratories for 14-3-3 analysis in the participating countries between 1998--2003 and clinical and pathological data were collected. CSF was obtained by LP and the analyses were conducted in each laboratory following standard protocols \[[@CR9]\]. An analysis of test validity and comparability between laboratories revealed high agreement between laboratories \[[@CR9]\]. Previously published cut-off values were used for the quantitative markers \[[@CR8], [@CR13]\].

In all countries, clinical and neuropathological data from patients with clinical suspicion of CJD or related disorders were collected. The diagnoses of CJD and various CJD subtypes were made according to the established criteria in all participating centers. Core clinical data such as age at onset, gender, disease duration, time point of the LP, codon 129 genotype, PrP^res^ type and final clinical and neuropathological diagnoses were centralized by each center. A database was set up, which included detailed data on the CSF markers and patients' characteristics. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Statistical analyses {#Sec4}
--------------------

Since the clinical duration within sCJD patients varies widely depending upon several variables (e.g., age at onset, gender, codon 129 polymorphism of the *PRNP* gene, and PrP^res^ type), the time interval between LP and disease onset is not an appropriate estimate of the stage of disease when the LP was performed. To overcome this problem, we divided the time of LP to disease onset in each patient by the total duration of the disease. Thus, we classified patients in three categories according to whether they underwent LP in the first (time of LP to disease onset/total duration of the disease \< 0.33), second (0.33--0.66) or third (\>0.66) stage of the disease. We analyzed the sensitivity of each marker at different stages of the disease. The differences in sensitivities across strata were analyzed using a logistic regression model adjusting for possible confounders and covariates. We also performed a stratified analysis by codon 129 *PRNP* genotype. In a similar way we assessed the absolute levels of quantitative markers across the different stages of the disease. The absolute levels of S100b obtained with different methods were analysed separately.

In order to evaluate the correlation between tau protein, S100b or NSE levels and disease duration we used the non-parametric correlation coefficient Spearman's Rho. Differences in CSF tau protein levels between patients with disease duration above or below the median (5 months) were compared using the Mann-Witney test. For the second part of the study, we selected patients who underwent more than one LP during the course of disease and then compared the sensitivity and evolution of each of the CJD markers. Differences in sensitivities were assessed using chi^2^ test.

Results {#Sec5}
=======

One thousand five hundred and fifty two samples from sCJD patients were studied. The time of LP and disease onset was available in 833 patients and the median time from onset to LP was 3 months (range 0.1--84.5). The LP was performed during the first stage of the disease in 16% (n = 137), during the second stage in 38% (n = 316), and in the final stage in 46% (n = 380). The median time from disease onset to LP in patients who underwent the LP in the first stage of the disease was 1.9 months (range 0.1--10.2); 2.3 months (0.2--23.6) in patients that underwent the LP in the second stage of the disease and 3.9 months (0.7--84.5) for those in the third stage. The data on test sensitivity for each marker stratified by the disease stage are given in Table 1. The sensitivity of 14-3-3 tended to increase from the first (88%) to the third stage of the disease (91%), although these differences were not statistically significant. When stratifying by codon 129 of *PRNP*, this trend became significant in the group of MV patients (p = 0.01).

Similar results were obtained for tau protein. There were not significant differences in the sensitivity of tau or in the median level of tau across the three disease stages (sensitivity of 81% in the first stage and 90.5% in the third stage, n = 342). However, when stratifying by codon 129, again the trend toward a higher sensitivity through the disease stages became significant in the group of MV patients (p = 0.048) (Table [1](#Tab1){ref-type="table"}). There was a trend of a gradual increase of tau levels in the MV patients, with the highest levels in the last stage (median 1202 pg/mL in the first stage, 1909 pg/mL in the second and 2601 in the third) and in VV patients (median 5949 pg/mL in the second and 10422 in the third stage of the disease). Table 1Sensitivity of markers in sporadic Creutzfeldt-Jakob disease at different disease stages, in the whole group and stratified by codon 129 *PRNP* genotype.first stage^†^Nsecond stage^†^Nthird stage^†^n*p* for trend\*Positive 14-3-387.6120/13788.0278/31691.3347/380NsMM94.079/8490.6155/17193.3166/178NsMV60.015/2569.837/5389.258/650.01VV100.06/695.744/4692.247/51NsPositive tau80.938/4784.9107/12690.5153/169NsMM83.926/3188.260/6892.979/85NsMV42.93/765.215/2380.625/310.048VV100.01/1100.017/1796.024/25NsPositive S100b73.027/3781.391/11293.9139/1480.01MM78.622/2881.448/5997.168/700.02MV25.01/466.710/1578.622/28NsVV0.00/189.517/19100.023/23NsPositive NSE82.533/4067.153/7982.781/980.01MM86.726/3068.931/4584.945/530.02MV50.02/441.75/1272.716/22NsVV0.00/176.910/1387.514/16Ns\* adjusted by country of origin, gender, disease duration, age of onset^†^ percentagesMM = methionine homozygous; MV = methionine/valine; VV = valine homozygousNSE = neurone specific enolase. The cut-off value for tau was 1,300pg/ml; for S100b 4.2 ng/ml, for the Byk-Sangtec® kit and 0.5 ng/ml for the, Non-commercial kit used in the United Kingdom; and 35 ng/ml for the Hoffman La Roche® kit and 25 ng/ml for Byk-Diasorin®, Byk-Sangtec® and Wallac® kits for NSE.

S100b levels were analysed in 297 samples, 37 in the first stage (12%), 112 in the second (38%), 148 in the third (50%.). The disease stage clearly influenced the S100b sensitivity with a significant increase (p = 0.01) in the latest stage (Table [1](#Tab1){ref-type="table"}). The absolute levels of S100b (Byk-Sangtec® kit) also increased across the disease (p \< 0.05).

NSE levels were assessed in 217 samples, and those obtained in the last stage gave a significantly higher sensitivity (83%) when compared to the second stage (67%, p = 0.01).

Levels of tau protein, S100b and NSE in CSF were negatively correlated with disease duration (nonparametric correlation coefficient Spearman's Rho = tau innogenetics −20% (p \< 0.001), S100b Byk-Sangtec® −17% (p = 0.002), S100b in house −18% (p = 0.01), NSE Hoffman-la Roche −21% (p = 0.001)). Patients with a median disease duration of 5 months or less had a median tau protein level of 6407 pg/mL (75-3623), whilst patients with a disease duration of longer than 5 months had a median tau protein level of 4411 pg/mL (75-47150), (Mann-Witney test p \< 0.001).

Sixty-six out of 1552 (4%) sCJD patients underwent more than one LP (at least two). The median time lapse between the LPs was 6 weeks. Forty-two (64%) of these cases were positive for 14-3-3 in the first LP (Figure [1](#Fig1){ref-type="fig"}). This value was different from the sensitivity in the whole group (85%, p \< 0.01). Fifty-four (82%) of sCJD cases had a positive 14-3-3 in the second sample (p = 0.025). Thirty-eight (57%) sCJD patients had a positive 14-3-3 in both samples, and 58 (88%) patients had at least one positive 14-3-3. Twenty sCJD patients (30%) changed their result for 14-3-3 in the second LP. Sixty-six percent of false negative sCJD became positive but 9.5% of those positive for 14-3-3 became negative in the second LP. Fig. 1Sensitivity of markers for sporadic Creutzfeldt-Jakob disease diagnosis in repeated lumbar punctures (LP) and combined results in both LP. LP = lumbar puncture, + = positive, NSE = neurone specific enolase, and = both LP+, or = either 1^st^ or 2^nd^+

The sensitivity of the other markers was also significantly lower in the first LP when compared to the whole group of sCJD (p \< 0.05). However, the sensitivity of these markers increased in the second sample when compared to the first, although not significantly. Eighty-one percent of sCJD cases had positive tau protein levels in one of the two LPs, but only 61% of cases had positive levels in both of them (Figure [1](#Fig1){ref-type="fig"}). With respect to S100b and NSE, 66% and 70% of sCJD patients had positive results in one of the two LPs and 53% and 33% in both of them, respectively.

We also found that the absolute levels of all three quantitative markers tended to increase in the second LP. This tendency was significant for S100b (median levels: 4.5 ng/ml (1--112) in the first LP, median levels: 7 ng/ml (1--38) in the second; p = 0.027) (Figure [2](#Fig2){ref-type="fig"}). In 39 out of 52 (75%) samples the levels of tau protein were higher in the second LP than in the first LP. NSE levels were higher in the second LP when compared to the first in 32 out of 46 (70%) samples, and S100b levels were higher in the second LP when compared to the first in 27 out of 38 (71%) samples. Fig. 2Levels of quantitative markers in repeated lumbar punctures. ^1^Differences between median levels were not significant. ^2^THe median S100b levels were different (p = 0.027). \*Byk-Sangtec kit

When we compared the characteristics of the sCJD patients who underwent repeated LP to the overall group of sCJD we found that these patients were younger at onset (mean age: 61years SD 9.8 vs. 66 years SD 9.6) and more frequently under 40 years (6% vs. 1%, p \< 0.001). They had a longer disease duration (mean: 12.8 months SD 8.7 vs. 7.9 months SD 7.8) and were more frequently heterozygous at codon 129 (p \< 0.001).

Discussion {#Sec6}
==========

Previous data about the influence of timing on the levels of CSF markers for CJD diagnosis are contradictory. The studies vary with respect to their methodology and often only single patients were included in the analysis. Jimi et al. \[[@CR5]\] showed in a sequential study that the levels of CJD markers increased during the course of the disease and returned to normal or mildly elevated levels in the terminal stage. Mollenhauer et al. \[[@CR7]\] also discussed the difficulties of CJD diagnosis in advanced cases presenting one sCJD case that became 14-3-3 negative in the final stage of the disease. On the other hand, Giraud et al. \[[@CR3]\] reported an increase in the levels of 14-3-3 proteins during the course of the disease in a limited number of sCJD cases. Brandel et al. \[[@CR2]\] performed a sequential study in iatrogenic CJD, and observed that 14-3-3 was rarely detectable within the first 3 months of the disease but always positive after 7 months associated with aggravation of the disease and the occurrence of dementia. The genotype at *PRNP* codon 129 influenced the timing of the rise of 14-3-3 in the CSF in these cases. Kropp et al. \[[@CR6]\] studied NSE levels in 16 sCJD patients with repeated LP. In 15 of them, NSE levels were higher in the second LP with respect to the first, but no other markers were studied and the disease duration or the *PRNP* genotype were not analysed. Finally, in a recent study, van Everbroeck et al. \[[@CR11]\] reported that in 42 sCJD patients the concentrations of 14-3-3 or tau protein were higher in the middle point of the disease (arbitrarily determined between the 25% and 85% of the total disease duration) than in the early or late stage.

In the framework of a multinational project, we studied the influence of timing on the CSF marker results in 833 sCJD patients. As the disease duration differs among CJD patients, we decided to analyse the influence of the stage of the disease, and not the absolute time to the disease onset or death, on the results of the CSF markers in order to avoid a bias towards the results in patients with shorter disease duration. On the other hand, in order to study the influence of timing on the different *PRNP* genotypes we also performed a stratified analysis by the *PRNP* genotype.

Our study showed a tendency for the sensitivity of all CSF markers to increase and for the absolute levels of the quantitative markers to rise during the course of the disease, using both the multivariate analysis and the assessment of the repeated LPs. Thus, CSF markers had the highest sensitivity at the third stage of disease. The codon 129 *PRNP* genotype modified this effect. The trend for a higher sensitivity of 14-3-3 and tau protein for sCJD diagnosis in the later stages of disease only became significant in the group of codon 129 MV patients. In addition we found that higher levels of tau protein were associated with a shorter survival, similiar to the results of another study, where CSF phosporylated tau protein levels were analysed \[[@CR10]\]. High levels of other brain-derived proteins (S100b, NSE) were also significantly associated with shorter survival. These brain-derived proteins are released into the CSF as a result of cell damage or death, and as such the levels of these markers reflect the rate of cell death are probably inversely related to disease duration. However, we should admit that we did not assess separately the sensitivity of the markers at very late stages of disease and we cannot rule out a possible final drop in sensitivity, paired to a slower rate of cell death at the final stage.

In those sCJD patients who had more than one LP performed, we found that the sensitivity of all CSF markers increased in the second LP when compared to the first LP. In more than 70% of all sCJD cases tested the absolute levels of the three quantitative markers also increased in the second LP. Sporadic CJD patients who underwent a second LP differed from the whole group, in that they were younger, had a longer disease duration and were more frequently heterozygous for *PRNP* codon 129 when compared to the whole group. These characteristics made them a more difficult group to diagnose and may explain why a second LP was performed. In this group of atypical sCJD patients a second LP increased the 14-3-3 sensitivity by 18%.

In conclusion, in our study we found that the sensitivity of the CSF markers for sCJD diagnosis increased during disease progression and that this was modulated by the codon 129 genotype. High levels of CSF brain-derived proteins were associated with a shorter survival. A negative CSF 14-3-3 result in the early stages should be interpreted with caution, especially in MV patients. Although performing a second LP is not usual clinical practice for the diagnosis of CJD, it may be useful to perform a second LP, 4--6 weeks after the initial one, in young patients, those with long clinical course or MV genotype.
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